The dynamics of genomic and transcriptomic features, including the PBRM1 mutation, metabolic process, active or exhausted immune types, and GATM expression, contributed to the responsiveness and prognosis to immunotherapy in metastatic ccRCC. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.